Key facts
- Abrinca Genomics’s last known valuation is $6.0M (May 2025).
- It has raised $430K; the latest was Early Stage VC ($1.8M) in Jun 2026.
- Notable investors include MassChallenge, Venture Kick, Kickfund, Stiftung für technologische Innovation.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Abrinca Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Abrinca Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abrinca Genomics
Developer of a microbial genome analysis platform designed to transform DNA data into usable insights. The company offers genome analysis, data management, and digital asset creation capabilities, enabling biotechnology and research organizations to derive value from genetic data and support bio-innovation.
- Sector
- Healthcare
- HQ
- Bern, Switzerland
- Founded
- 2023
- Employees
- 3
- Website
- abrinca.com/
- Ownership
- Privately Held (backing)
Abrinca Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abrinca Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abrinca Genomics in its N-PORT filings yet. We sweep new filings monthly.